Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A ...
Feb 25, 2025 · Here we review the evidence on taxane-based therapy, including cabazitaxel, in the treatment of PC, with a focus on clinical and real-world evidence from Japan. Cabazitaxel …
Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate ...
Abstract Background: For post-docetaxel treatment of metastatic castrate-resistant prostate cancer (mCRPC), cabazitaxel has demonstrated superior third line PFS and OS compared to …
Survival outcomes based on line of therapy and treatment trends …
Feb 18, 2025 · However, real-world data on the efficacy and trends of cabazitaxel usage remain limited. Herein, we aimed to assess the survival outcomes and treatment patterns in pts with …
Cabazitaxel Emerges as Third-Line Standard for Metastatic CRPC
Oct 1, 2019 · Men who received cabazitaxel (Jevtana) as a third-line systemic agent for metastatic castration-resistant prostate cancer had a significant reduction in radiographic …
Cabazitaxel versus docetaxel for treatment of metastatic castrate ...
To assess cabazitaxel versus docetaxel re‐challenge for the treatment of metastatic castrate refractory prostate cancer (CRPC) patients previously treated with docetaxel at inception of …
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic …
Sep 30, 2019 · The efficacy and safety of cabazitaxel, as compared with an androgen-signaling–targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic …
Cabazitaxel in the treatment of metastatic castration-resistant ...
Abstract Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new …
Efficacy of Early Switching From Docetaxel to Cabazitaxel in
Early switching to cabazitaxel after three cycles of docetaxel may reduce symptomatic adverse events, including peripheral neuropathy, while enabling longer chemotherapy exposure and …
Reponse to Cabazitaxel in the Postchemotherapy Setting in Crpc …
Cabazitaxel (a tubulin-binding taxane chemotherapy) and Abiraterone acetate (AA) have recently been approved for patients with metastatic castration resistant prostate cancer (CRPC) …
Comparative efficacy and safety of cabazitaxel versus other …
Oct 31, 2025 · Background and objectives This systematic review addresses uncertainty around cabazitaxel's effectiveness, safety, and optimal dosing compared to other taxanes, aiming to …